Identification, Evaluation and Treatment of Prasugrel Low-Response after Coronary Stent Implantation - A Preliminary Study

被引：16

作者：

Neubauer, Horst ^{[1
]}

Kaiser, Andreas ^{[1
]}

Busse, Birgit ^{[2
]}

Muegge, A. ^{[1
]}

机构：

[1] Ruhr Univ Bochum, St Josef Hosp, Ctr Cardiovasc, D-44791 Bochum, Germany

[2] Ctr Human Genet & Lab Med, D-82152 Martinsried, Germany

来源：

THROMBOSIS RESEARCH | 2010年 / 126卷 / 05期

关键词：

Clopidogrel; Prasugrel; Low Responder; Platelet aggregation; Cytochrome P450; CLOPIDOGREL; POLYMORPHISMS;

D O I：

10.1016/j.thromres.2010.06.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E389 / E391

页数：3

共 11 条

[1] A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation [J].

Brandt, John T. ;

Payne, Christopher D. ;

Wiviott, Stephen D. ;

Weerakkody, Govinda ;

Farid, Nagy A. ;

Small, David S. ;

Jaknbowski, Joseph A. ;

Naganuma, Hideo ;

Winters, Kenneth J. .

AMERICAN HEART JOURNAL, 2007, 153 (01) :66.e9-66.e16

[2] New P2Y12 blockers [J].

Cattaneo, M. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 :262-265

[3] Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans [J].

Farid, Nagy A. ;

Kurihara, Atsushi ;

Wrighton, Steven A. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (02) :126-142

[4] Drug insight: clopidogrel nonresponsiveness [J].

Gurbel, Paul A. ;

Tantry, Udaya S. .

NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (07) :387-395

[5] Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects [J].

Ingelman-Sundberg, Magnus ;

Sim, Sarah C. ;

Gomez, Alvin ;

Rodriguez-Antona, Cristina .

PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) :496-526

[6] Dual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention [J].

Ivandic, Boris T. ;

Sausemuth, Mareike ;

Ibrahim, Hesham ;

Giannitsis, Evangelos ;

Gawaz, Meinrad ;

Katus, Hugo A. .

CLINICAL CHEMISTRY, 2009, 55 (06) :1171-1176

[7] Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease [J].

Jernberg, T ;

Payne, CD ;

Winters, KJ ;

Darstein, C ;

Brandt, JT ;

Jakubowski, JA ;

Naganuma, H ;

Siegbahn, A ;

Wallentin, L .

EUROPEAN HEART JOURNAL, 2006, 27 (10) :1166-1173

[8] Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes [J].

Mega, Jessica L. ;

Close, Sandra L. ;

Wiviott, Stephen D. ;

Shen, Lei ;

Hockett, Richard D. ;

Brandt, John T. ;

Walker, Joseph R. ;

Antman, Elliott M. ;

Macias, William L. ;

Braunwald, Eugene ;

Sabatine, Marc S. .

CIRCULATION, 2009, 119 (19) :2553-U44

[9] How to optimise clopidogrel therapy?: Reducing the low-response incidence by aggregometry-guided therapy modification [J].

Neubauer, Horst ;

Lask, Sebastian ;

Engelhardt, Andreas ;

Muegge, Andreas .

THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) :357-362

[10] Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 [J].

Rehmel, JLF ;

Eckstein, JA ;

Farid, NA ;

Heim, JB ;

Kasper, SC ;

Kurihara, A ;

Wrighton, SA ;

Ring, BJ .

DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) :600-607

← 1 2 →